

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	1	of	23				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		4,806,463		Goodchild et al.	02-21-1989
		5,004,810		Draper	04-02-1991
		5,023,243		Tullis	06-11-1991
		5,166,195		Ecker	11-24-1992
		5,248,670		Draper et al.	09-28-1993
		5,264,423		Cohen et al.	11-23-1993
		5,276,019		Cohen et al.	01-04-1994
		5,457,189		Crooke et al.	10-10-1995
		5,514,577		Draper et al.	05-07-1996
		5,565,354		Ostberg et al.	10-15-1996
		5,567,604		Rando et al.	10-22-1996
		5,576,302		Cook et al.	11-19-1996
		5,594,122		Friesen	01-14-1997
		5,658,891		Draper et al.	08-19-1997
		5,663,153		Hutcherson et al.	09-02-1997
		5,665,580		Crooke et al.	09-09-1997
		5,681,944		Crooke et al.	11-04-1997
		5,684,147		Agrawal et al.	11-04-1997
		5,723,335		Hutcherson et al.	03-03-1998
		5,728,518		Carmichael	03-17-1998
		5,780,448		Davis	07-14-1998
		5,817,637		Weiner et al.	10-06-1998
		5,843,770		Ill et al.	12-01-1998
		5,854,418		Chang et al.	12-29-1998
		5,858,987		Beer-Romero et al.	01-12-1999
		5,985,662		Anderson et al.	11-16-1999
		6,030,955		Stein et al.	02-29-2000
		6,107,062		Hu et al.	08-22-2000
		6,114,167		Symonds et al.	09-05-2000
		6,133,244		Michel et al.	10-17-2000
		6,147,123		Chojkier et al.	11-14-2000

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
-------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01			
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683			
				APPLICANT: Ahluwalia et al.					
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le			
Sheet	2	of	23						

	6,194,352	B1	Rando et al.	02-06-2001
	6,194,388	B1	Krieg et al.	02-27-2001
	6,207,646	B1	Krieg et al.	03-27-2001
	6,214,806	B1	Krieg et al.	04-10-2001
	6,218,371	B1	Krieg et al.	04-17-2001
	6,221,882	B1	Macfarlane	04-24-2001
	6,239,116	B1	Krieg et al.	05-29-2001
	6,339,068	B1	Krieg et al.	01-15-2002
	6,399,630	B1	Macfarlane	06-04-2002
	6,406,705	B1	Davis et al.	06-18-2002
	6,429,199	B1	Krieg et al.	08-06-2002
	6,479,504	B1	Macfarlane et al.	11-12-2002
	6,498,147	B1	Nerenberg et al.	12-24-2002
	6,503,533	B1	Korba et al.	01-07-2003
	6,514,948	B1	Raz et al.	02-04-2003
	6,521,637	B2	Macfarlane	02-18-2003
	6,534,062	B1	Raz et al.	03-18-2003
	6,552,006	B2	Raz et al.	04-22-2003
	6,558,670	B1	Friede et al.	05-06-2003
	6,562,798	B1	Schwartz	05-13-2003
	6,589,940	B1	Raz et al.	07-08-2003
	6,610,308	B1	Haensler	08-26-2003
	6,610,661	B1	Carson et al.	08-26-2003
	6,653,292	B1	Krieg et al.	11-25-2003
	6,727,230	B1	Hutcherson et al.	04-27-2004
	6,737,066	B1	Moss	05-18-2004
	6,821,957	B1	Krieg et al.	11-23-2004
	6,835,395	B1	Semple et al.	12-28-2004
	6,943,240	B2	Bauer et al.	09-13-2005
	6,949,520	B1	Hartmann et al.	09-27-2005
	6,962,709	B2	Koelle et al.	11-08-2005
	6,984,729	B1	Frank et al.	01-10-2006
	7,001,890	B1	Wagner et al.	02-21-2006
	7,157,437	B2	Van Nest	01-02-2007

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
-------------------------	------------------------------------

⁶ EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	3	of	23				

		7,223,741	B2	Krieg	05-29-2007
		7,271,156	B2	Krieg et al.	07-18-2007
		7,354,711	B2	Macfarlane	04-08-2008
		7,402,572	B2	Krieg et al.	07-22-2008
		7,410,975	B2	Lipford et al.	04-08-2008
		7,488,490	B2	Davis et al.	02-10-2009
		7,517,861	B2	Krieg et al.	04-14-2009
		7,524,828	B2	Krieg et al.	04-28-2009
		7,534,772	B2	Weiner et al.	05-19-2009
		7,566,703	B2	Krieg et al.	07-28-2009
		7,569,553	B2	Krieg	08-04-2009
		7,576,066	B2	Krieg	08-18-2009
		7,585,847	B2	Bratzler et al.	09-08-2009
		7,605,138	B2	Krieg	10-20-2009
		2001-0044416	A1	McCluskie et al.	11-22-2001
		2001-0046967	A1	Van Nest et al.	11-29-2001
		2002-0028784	A1	Van Nest et al.	03-07-2002
		2002-0064515	A1	Krieg et al.	05-30-2002
		2002-0065236	A1	Yew et al.	05-30-2002
		2002-0091097	A1	Bratzler et al.	07-11-2002
		2002-0098199	A1	Van Nest et al.	07-25-2002
		2002-0107212	A1	Van Nest et al.	08-08-2002
		2002-0142977	A1	Raz et al.	10-03-2002
		2002-0156033	A1	Bratzler et al.	10-24-2002
		2002-0164341	A1	Davis et al.	11-07-2002
		2002-0165178	A1	Schetter et al.	11-07-2002
		2002-0168340	A1	Agrawal	11-14-2002
		2002-0192184	A1	Carpentier et al.	12-19-2002
		2002-0198165	A1	Bratzler et al.	12-26-2002
		2003-0026782	A1	Krieg	02-02-2003
		2003-0026801	A1	Weiner et al.	02-06-2003
		2003-0050261	A1	Krieg et al.	03-13-2003
		2003-0050263	A1	Krieg et al.	03-13-2003
		2003-0050268	A1	Krieg et al.	03-13-2003

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
-------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	4	of	23				

		2003-0055014	A1	Bratzler	03-20-2003
		2003-0072762	A1	Van de Winkel et al.	04-17-2003
		2003-0091599	A1	Davis et al.	05-15-2003
		2003-0100527	A1	Krieg et al.	05-29-2003
		2003-0119773	A1	Raz et al.	06-26-2003
		2003-0125279	A1	Junghans et al.	07-03-2003
		2003-0139364	A1	Krieg et al.	07-24-2003
		2003-0143213	A1	Raz et al.	07-31-2003
		2003-0148316	A1	Lipford et al.	09-04-2003
		2003-0147870	A1	Raz et al.	08-07-2003
		2003-0148316	A1	Lipford et al.	08-07-2003
		2003-0148976	A1	Krieg et al.	08-07-2003
		2003-0166001	A1	Lipford	09-04-2003
		2003-0176389	A1	Raz et al.	09-18-2003
		2003-0181406	A1	Schetter et al.	09-25-2003
		2003-0186921	A1	Carson et al.	10-02-2003
		2003-0191079	A1	Krieg et al.	10-09-2003
		2003-0199466	A1	Fearon et al.	10-23-2003
		2003-0212028	A1	Raz et al.	11-13-2003
		2003-0216340	A1	Van Nest et al.	11-20-2003
		2003-0224010	A1	Davis et al.	12-04-2003
		2003-0232074	A1	Lipford et al.	12-18-2003
		2003-0232856	A1	Macfarlane	12-18-2003
		2004-0006010	A1	Carson et al.	01-08-2004
		2004-0006034	A1	Raz et al.	01-08-2004
		2004-0009942	A1	Van Nest et al.	01-15-2004
		2004-0009949	A1	Krieg	01-15-2004
		2004-0030118	A1	Wagner et al.	02-12-2004
		2004-0038922	A1	Haensler et al.	02-26-2004
		2004-0047869	A1	Garcon et al.	03-11-2004
		2004-0053880	A1	Krieg	03-18-2004
		2004-0067902	A9	Bratzler et al.	04-08-2004
		2004-0067905	A1	Krieg	04-08-2004
		2004-0087534	A1	Krieg et al.	05-06-2004

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
---------------------	--------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	5	of	23				

		2004-0087538	A1	Krieg et al.	05-06-2004
		2004-0092472	A1	Krieg	05-13-2004
		2004-0092468	A1	Schwartz et al.	05-13-2004
		2004-0105872	A1	Klinman et al.	06-03-2004
		2004-0106568	A1	Krieg et al.	06-03-2004
		2004-0115219	A1	Ahn et al.	06-17-2004
		2004-0131628	A1	Bratzler et al.	07-08-2004
		2004-0132685	A1	Krieg et al.	07-08-2004
		2004-0136948	A1	Fearon et al.	07-08-2004
		2004-0142469	A1	Krieg et al.	07-22-2004
		2004-0143112	A1	Krieg et al.	07-22-2004
		2004-0147468	A1	Krieg et al.	07-29-2004
		2004-0152649	A1	Krieg	08-05-2004
		2004-0152656	A1	Krieg et al.	08-05-2004
		2004-0152657	A1	Krieg et al.	08-05-2004
		2004-0162258	A1	Krieg et al.	08-19-2004
		2004-0162262	A1	Krieg et al.	08-19-2004
		2004-0167089	A1	Krieg et al.	08-26-2004
		2004-0171150	A1	Krieg et al.	09-02-2004
		2004-0171571	A1	Krieg et al.	09-02-2004
		2004-0181045	A1	Krieg et al.	09-16-2004
		2004-0191833	A1	Fink et al.	09-30-2004
		2004-0198680	A1	Krieg	10-07-2004
		2004-0198688	A1	Krieg et al.	10-07-2004
		2004-0229835	A1	Krieg et al.	11-18-2004
		2004-0234512	A1	Wagner et al.	11-25-2004
		2004-0235770	A1	Davis et al.	11-25-2004
		2004-0235774	A1	Bratzler et al.	11-25-2004
		2004-0235777	A1	Wagner et al.	11-25-2004
		2004-0235778	A1	Wagner et al.	11-25-2004
		2004-0247662	A1	Dow et al.	12-09-2004
		2004-0266719	A1	McCluskie et al.	12-30-2004
		2005-0004061	A1	Krieg et al.	01-06-2005
		2005-0004062	A1	Krieg et al.	01-06-2005

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
-------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	6	of	23				

		2005-0004144	A1	Carson et al.	01-06-2005
		2005-0009774	A1	Krieg et al.	01-13-2005
		2005-0013812	A1	Dow et al.	01-20-2005
		2005-0031638	A1	Dalemans et al.	02-10-2005
		2005-0032734	A1	Davis et al.	02-10-2005
		2005-0032734	A1	Krieg et al.	02-10-2005
		2005-0037403	A1	Krieg et al.	02-17-2005
		2005-0037985	A1	Krieg et al.	02-17-2005
		2005-0043529	A1	Davis et al.	02-24-2005
		2005-0049215	A1	Krieg et al.	03-03-2005
		2005-0049216	A1	Krieg et al.	03-03-2005
		2005-0054590	A1	Averett	03-10-2005
		2005-0054601	A1	Wagner et al.	03-10-2005
		2005-0054602	A1	Krieg et al.	03-10-2005
		2005-0059619	A1	Krieg et al.	03-17-2005
		2005-0059625	A1	Krieg et al.	03-17-2005
		2005-0059626	A1	Van Nest et al.	03-17-2005
		2005-0064401	A1	Olek et al.	03-24-2005
		2005-0070491	A1	Krieg et al.	03-31-2005
		2005-0075302	A1	Hutcherson et al.	04-07-2005
		2005-0079152	A1	Bot et al.	04-14-2005
		2005-0100983	A1	Bauer et al.	05-12-2005
		2005-0101554	A1	Krieg et al.	05-12-2005
		2005-0101557	A1	Krieg et al.	05-12-2005
		2005-0119273	A1	Lipford et al.	06-02-2005
		2005-0123523	A1	Krieg et al.	06-09-2005
		2005-0130911	A1	Uhlmann et al.	06-16-2005
		2005-0148537	A1	Krieg et al.	07-07-2005
		2005-0169888	A1	Hartman et al.	08-04-2005
		2005-0171047	A1	Krieg et al.	08-04-2005
		2005-0181422	A1	Bauer et al.	08-18-2005
		2005-0182017	A1	Krieg	08-18-2005
		2005-0196411	A1	Moss et al.	09-08-2005
		2005-0197314	A1	Krieg et al.	09-08-2005

EXAMINER:	DATE CONSIDERED:
/E.L./	06/09/2010

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	7	of	23				

		2005-0209184	A1	Klinman et al.	09-22-2005
		2005-0215501	A1	Krieg et al.	09-29-2005
		2005-0215501	A1	Lipford et al.	09-29-2005
		2005-0233999	A1	Krieg et al.	10-20-2005
		2005-0233999	A1	Krieg et al.	10-20-2005
		2005-0239732	A1	Krieg et al.	10-27-2005
		2005-0239733	A1	Jurk et al.	10-20-2005
		2005-0239733	A1	Uhlmann et al.	10-27-2005
		2005-0239736	A1	Krieg et al.	10-27-2005
		2005-0244379	A1	Krieg et al.	11-03-2005
		2005-0244380	A1	Krieg et al.	11-03-2005
		2005-0245477	A1	Krieg et al.	11-03-2005
		2005-0250726	A1	Krieg et al.	11-10-2005
		2005-0255124	A1	Houghton et al.	11-17-2005
		2005-0256073	A1	Lipford et al.	11-17-2005
		2005-0266015	A1	Clerici et al.	12-01-2005
		2005-0266025	A1	Voss	12-01-2005
		2005-0267064	A1	Krieg et al.	12-01-2005
		2005-0277604	A1	Krieg et al.	12-15-2005
		2005-0277609	A1	Krieg et al.	12-15-2005
		2005-0287167	A1	zur Megede et al.	12-29-2005
		2006-0003955	A1	Krieg et al.	01-05-2006
		2006-0003962	A1	Ahluwalia et al.	01-05-2006
		2006-0019239	A1	Ivins et al.	01-26-2006
		2006-0019916	A1	Krieg et al.	01-26-2006
		2006-0019923	A1	Davis et al.	01-26-2006
		2006-0058251	A1	Krieg et al.	03-16-2006
		2006-0089326	A1	Krieg et al.	04-27-2006
		2006-0094683	A1	Krieg et al.	05-04-2006
		2006-0140875	A1	Krieg et al.	06-29-2006
		2006-0154890	A1	Bratzler et al.	07-13-2006
		2006-0165713	A1	Gough et al.	07-27-2006
		2006-0172966	A1	Lipford et al.	08-03-2006
		2006-0188913	A1	Krieg et al.	08-24-2006

EXAMINER:	/E.L./	DATE CONSIDERED:	06/09/2010
-----------	--------	------------------	------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	8	of	23				

		2006-0211639	A1	Bratzler et al.	09-21-2006
		2006-0211644	A1	Krieg et al.	09-21-2006
		2006-0229271	A1	Krieg et al.	10-12-2006
		2006-0241076	A1	Uhlmann et al.	10-26-2006
		2006-0251623	A1	Bachmann et al.	11-09-2006
		2006-0251677	A1	Bachmann et al.	11-09-2006
		2006-0264391	A1	Van Nest	11-23-2006
		2006-0286070	A1	Hartmann et al.	12-21-2006
		2006-0287263	A1	Davis et al.	12-21-2006
		2007-0009482	A1	Krieg et al.	01-11-2007
		2007-0010470	A1	Krieg et al.	01-11-2007
		2007-0037767	A1	Bratzler et al.	02-15-2007
		2007-0065467	A1	Krieg et al.	03-22-2007
		2007-0066553	A1	Krieg et al.	03-22-2007
		2007-0066554	A1	Krieg et al.	03-22-2007
		2007-0078104	A1	Krieg et al.	04-05-2007
		2007-0129320	A9	Davis et al.	06-07-2007
		2007-0142315	A1	Forsbach et al.	06-21-2007
		2007-0184465	A1	Wagner et al.	08-09-2007
		2007-0202128	A1	Krieg et al.	08-30-2007
		2007-0224210	A1	Krieg et al.	09-27-2007
		2007-0232622	A1	Lipford et al.	10-04-2007
		2008-0009455	A9	Krieg et al.	01-10-2008
		2008-0026011	A1	Krieg et al.	01-31-2008
		2008-0031936	A1	Krieg et al.	02-07-2008
		2008-0045473	A1	Uhlmann et al.	02-21-2008
		2008-0113929	A1	Lipford et al.	05-15-2008
		2008-0226649	A1	Schetter et al.	09-18-2008
		2009-0017021	A1	Davis et al.	01-15-2009
		2009-0060927	A1	Wagner et al.	03-05-2009
		2009-0142362	A1	Krieg et al.	06-04-2009
		2009-0155307	A1	Davis et al.	06-18-2009
		2009-0155212	A1	Bratzler et al.	06-18-2009
		2009-0191188	A1	Krieg et al.	07-30-2009

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
------------------	-----------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	9	of	23				

		2009-0202575	A1	Krieg et al.	08-13-2009
		2009-0214578	A1	Bauer	08-27-2009

FOREIGN PATENT DOCUMENTS

Examiner's Initials *	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		CN	1 468 957		Military Medical Univ	01-21-2004	Y-Abstract
		EP	0 302 758	A1	New England Medical Center Hospitals,	02-08-1989	
		EP	0 468 520	A2	Mitsui Toatsu Chemicals, Inc.	01-29-1992	
		KR	2001063153		Genexine Inc.	07-09-2001	Y-Abstract
		WO	91/12811	A1	ISIS Pharmaceuticals Inc.	09-05-1991	
		WO	92/03456	A1	ISIS Pharmaceuticals Inc.	03-05-1992	
		WO	93/15207	A2	Viagene Inc.	08-05-1993	
		WO	94/16737	A1	Wiener et al.	08-04-1994	
		WO	94/19945	A1	ISIS Pharmaceuticals Inc.	09-15-1994	
		WO	95/03407	A2	Gen-Probe Incorporated	02-02-1995	
		WO	96/02555	A1	University of Iowa Research Foundation	02-01-1996	
		WO	97/28259	A1	The Regents of the University of California	08-07-1997	
		WO	98/16247	A1	The Regents of the University of California	04-23-1998	
		WO	98/32462	A1	Wagner et al.	07-30-1998	
		WO	98/49288	A1	Hybridon Inc.	11-05-1998	
		WO	98/55495	A2	Dynavax Technologies Corporation	12-10-1998	
		WO	99/33488	A2	SmithKline Beecham Biologicals S.A.	07-08-1999	
		WO	99/52549	A1	SmithKline Beecham Biologicals S.A.	10-29-1999	
		WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
		WO	99/62923	A2	Dynavax Technologies Corporation	12-09-1999	
		WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000	
		WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
		WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Y-Abstract
		WO	00/20039	A1	The Regents of the University of California	04-13-2000	
		WO	00/21556	A1	Dynavax Technologies Corporation	04-20-2000	

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
-------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 10 of 23

APPLICATION NO.: 10/532,746

ATTY. DOCKET NO.: C1037.70035US01

FILING DATE: September 9, 2005

CONFIRMATION NO.: 2683

APPLICANT: Ahluwalia et al.

GROUP ART UNIT: 1648

EXAMINER: Emily M. Le

	WO	00/41463	A2	SmithKline Beecham Biologicals, S.A.	07-20-2000	
	WO	00/54803	A2	Panacea Pharmaceuticals, LLC.	09-21-2000	
	WO	00/61151	A2	The Government of the United States of	10-19-2000	
	WO	00/62787	A1	Regents of the University of California	10-26-2000	
	WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	
	WO	00/67787	A2	The Immune Response Corporation	11-16-2000	
	WO	01/00232	A2	SmithKline Beecham Biologicals, S.A.	01-04-2001	
	WO	01/02007	A1	Regents of the University of California	01-11-2001	
	WO	01/12223	A2	Dynavax Technologies Corporation	02-22-2001	
	WO	01/17550	A2	SmithKline Beecham Biologicals, S.A.	03-15-2001	
	WO	01/17551	A2	SmithKline Beecham Biologicals, S.A.	03-15-2001	
	WO	01/22990	A2	Coley Pharmaceutical Group, Inc.	04-05-2001	
	WO	01/35991	A2	Dynavax Technologies Corporation	05-25-2001	
	WO	01/45750	A1	Regents of the University of California	06-28-2001	
	WO	01/54719	A2	SmithKline Beecham Biologicals, S.A.	08-02-2001	
	WO	01/55341	A2	Regents of the University of California	08-02-2001	
	WO	01/68077	A2	Dynavax Technologies Corporation	09-20-2001	
	WO	01/68078	A2	Dynavax Technologies Corporation	09-20-2001	
	WO	01/68103	A2	Dynavax Technologies Corporation	09-20-2001	
	WO	01/68116	A2	Dynavax Technologies Corporation	09-20-2001	
	WO	01/68117	A2	Dynavax Technologies Corporation	09-20-2001	
	WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Y-Abstract
	WO	03/002065	A2	Chiron Corporation	01-09-2003	
	WO	03/020889	A2	3M Innovative Properties Company	03-13-2003	
	WO	03/024481	A2	Cytos Biotechnology AG	03-27-2003	
	WO	03/025119	A2	Medarex Inc.	03-27-2003	
	WO	03/030656	A2	Qiagen GMBH [DE]	04-17-2003	
	WO	03/035836	A2	Hybridon, Inc.	05-01-2003	
	WO	03/043572	A2	3M Innovative Properties Company	05-30-2003	
	WO	03/094963	A2	INEX Pharmaceuticals Corp.	11-20-2003	
	WO	03/100040	A1	Merck Patent GMBH	12-04-2003	
	WO	2004/007743	A2	Coley Pharmaceutical GmbH	01-22-2004	
	WO	2004/026888	A2	Coley Pharmaceutical GMBH	04-01-2004	
	WO	2004/094671	A2	Coley Pharmaceutical GMBH	11-04-2004	

EXAMINER:

/E.L./

DATE CONSIDERED:

06/09/2010

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/532,746

ATTY. DOCKET NO.: C1037.70035US01

FILING DATE: September 9, 2005

CONFIRMATION NO.: 2683

APPLICANT: Ahluwalia et al.

GROUP ART UNIT: 1648

EXAMINER: Emily M. Le

Sheet 11 of 23

	WO	2005/004907	A1	Cytos Biotechnology AG	01-20-2005	
	WO	2005/004910	A2	Intercell Ag	01-20-2005	
	WO	2005/023289	A1	Intellectual Property Consulting	03-17-2005	Y-Abstract
	WO	2005/025583	A2	Anadys Pharmaceuticals, Inc.	03-24-2005	
	WO	2005/079419	A2	The Regents of the University of California	09-01-2005	
	WO	2006/032674	A1	Cytos Biotechnology AG	03-30-2006	
	WO	2006/080946	A2	Coley Pharmaceutical GMBH	08-03-2006	
	WO	2006/108358	A1	Changchun Huapu Biotechnology Co.,	10-19-2006	Y-Abstract
	WO	2007/031877	A2	Coley Pharmaceutical GMBH	03-22-2007	
	WO	2007/038720	A2	Coley Pharmaceutical GMBH	04-05-2007	
	WO	2007/068747	A1	Cytos Biotechnology AG	06-21-2007	
	WO	2008/030455	A2	Coley Pharmaceutical Group, Inc.	03-13-2008	
	WO	2008/033432	A2	Coley Pharmaceutical Group, Inc.	03-20-2008	
	WO	2008/039538	A2	Coley Pharmaceutical Group, Inc.	04-03-2008	
	WO	2008/068638	A2	Coley Pharmaceutical GMBH	06-12-2008	
	WO	2008/139262	A2	Coley Pharmaceutical GMBH	11-20-2008	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials ^a	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] Antiviral Agents Bulletin. 5(6), 1992.	
		[No Author Listed] CPG10101 HCV Toll-Receptor 9 Antagonist Phase II Study Results. 57 th Annual Meeting of the American Association for the Study of Liver Diseases. October 27-31, 2006. Boston, MA. 9 pages.	
		AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar;8(3):114-21.	
		AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. 1998:525-43.	
		AGRAWAL et al., Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995 Jan;28(1):7-16. Review.	
		AGRAWAL et al., Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci U S A. 1989 Oct;86(20):7790-4.	
		AHLUWALIA et al., Immunostimulatory profiles from two classes of CpG ODN administered subcutaneously to healthy subjects. ICI FOCIS 2004. Poster.	
		ASKEW et al., CpG DNA induces maturation of dendritic cells with distinct effects on nascent and	

EXAMINER:

/E.L./

DATE CONSIDERED:

06/09/2010

^a EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet	12	of	23
-------	----	----	----

APPLICATION NO.: 10/532,746	ATTY. DOCKET NO.: C1037.70035US01
FILING DATE: September 9, 2005	CONFIRMATION NO.: 2683
APPLICANT: Ahluwalia et al.	
GROUP ART UNIT: 1648	EXAMINER: Emily M. Le

	recycling MHC-II antigen-processing mechanisms. <i>J Immunol.</i> 2000 Dec 15;165(12):6889-95.	
	AZAD et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. <i>Antimicrob Agents Chemother.</i> 1993 Sep;37(9):1945-54.	
	BAIN et al., Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. <i>Gastroenterology.</i> 2001 Feb;120(2):512-24.	
	BALLAS et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol.</i> 1996 Sep 1;157(5):1840-5.	
	BASSETT et al., Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. <i>Hepatology.</i> 2001 Jun;33(6):1479-87.	
	BAUER et al., Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. <i>Proc Natl Acad Sci U S A.</i> 2001 Jul 31;98(16):9237-42.	
	BAUER et al., DNA activates human immune cells through a CpG sequence-dependent manner. <i>Immunology.</i> 1999 Aug;97(4):699-705.	
	BAUER et al., Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. <i>J Immunol.</i> 2001 Apr 15;166(8):5000-7.	
	BOGGS et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):461-71.	
	BRANDA et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. <i>Biochem Pharmacol.</i> 1993 May 25;45(10):2037-43.	
	BRANDA et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. <i>J Lab Clin Med.</i> 1996 Sep;128(3):329-38.	
	BRANDA et al., B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. <i>Clin Immunol Immunopathol.</i> 1996 May;79(2):115-21.	
	BRAZOLOT MILLAN et al., CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. <i>Proc Natl Acad Sci U S A.</i> 1998 Dec 22;95(26):15553-8.	
	CACCIARELLI et al., Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. <i>Hepatology.</i> 1996 Jul;24(1):6-9.	
	CALAROTA et al., Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. <i>Lancet.</i> 1998 May 2;351(9112):1320-5.	
	CATTANEO et al., Signals regulating hepatitis B surface antigen transcription. <i>Nature.</i> 1983 Sep 22-28;305(5932):336-8.	
	CELLA et al., Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. <i>Nat Med.</i> 1999 Aug;5(8):919-23.	
	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. <i>Clin Immunol Immunopathol.</i> 1997 Aug;84(2):185-93.	
	CHAN et al., CpG-A and CpG-B oligodeoxynucleotides differentially affect the cytokine profile, chemokine receptor expression and T-cell priming function of human plasmacytoid dendritic cells. <i>Blood.</i> 2002;100:50b. Abstract #3666.	
	CHU et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper I (Th1) immunity.	

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
---------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	13	of	23				

		J Exp Med. 1997 Nov 17;186(10):1623-31.	
		COLLETTE et al., Specific Th1 cytokine down-regulation associated with primary clinically derived human immunodeficiency virus type 1 Nef gene-induced expression. J Immunol. 1996 Jan 1;156(1):360-70.	
		COOPER et al., Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluairix influenza vaccine. Vaccine. 2004 Aug 13;22(23-24):3136-43.	
		COOPER et al., CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005 Sep 23;19(14):1473-9.	
		COOPER et al., CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov;24(6):693-701.	
		COSSUM et al., Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993 Dec;267(3):1181-90.	
		COWDERY et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol. 1996 Jun 15;156(12):4570-5.	
		COWSERT et al., In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993 Feb;37(2):171-7.	
		DALOD et al., Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med. 2002 Feb 18;195(4):517-28.	
		DALPKE et al., CpG DNA in the prevention and treatment of infections. BioDrugs. 2002;16(6):419-31. Abstract only.	
		DAVIS et al., CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 1998 Jan 15;160(2):870-6.	
		DAVIS, Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol. 2000;247:171-83.	
		DAVIS et al., CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of Phase I trial with CpG ODN 7909. Third Annual Conference on Vaccine Res. 2000. Abstract s25, number 47.	
		DAVIS et al., CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 2000 Mar 17;18(18):1920-4.	
		FIELDS et al., Fields' Virology. 2001;1:1153.	
		GALLICHAN et al., Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol. 2001 Mar 1;166(5):3451-7.	
		GEISSLER et al., Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 1997 Feb 1;158(3):1231-7.	
		GOLDBERG et al., Beyond danger: unmethylated CpG dinucleotides and the immunopathogenesis of disease. Immunol Lett. 2000 Jul 3;73(1):13-8.	
		GRAMZINSKI et al., Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med. 1998	

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
---------------------	--------------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/532,746

ATTY. DOCKET NO.: C1037.70035US01

FILING DATE: September 9, 2005

CONFIRMATION NO.: 2683

APPLICANT: Ahluwalia et al.

GROUP ART UNIT: 1648

EXAMINER: Emily M. Le

Sheet 14 of 23

Feb;4(2):109-18.

HALPERIN et al., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 2003 Jun 2;21(19-20):2461-7.

HALPERN et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 1996 Jan 10;167(1):72-8.

HARANDI et al., A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol. 2003 Jan;77(2):953-62.

HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999 May;6(5):893-903.

HARTMANN et al., Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000 Jan 15;164(2):944-53.

HARTMANN et al., Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000 Feb 1;164(3):1617-24.

HARTMANN et al., CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9305-10.

HEEG et al., CpG DNA as a Th1 trigger. Int Arch Allergy Immunol. 2000 Feb;121(2):87-97.

HERBST et al., Immunostimulatory CpG treatment for genital HSV-2 infections. J Antimicrob Chemother. 2003 Dec;52(6):887-9. Epub 2003 Oct 29. Review.

HO, Toward HIV eradication or remission: the tasks ahead. Science. 1998 Jun 19;280(5371):1866-7.

HOPKIN et al., Curbing the CpGs of Bacterial and Viral DNA. BioMedNet. 1999 Jun 25; Issue 57.

HORNER et al., Mucosal adjuvanticity of immunostimulatory DNA sequences. Springer Semin Immunopathol. 2000;22(1-2):133-46.

HUANG et al., Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria. Infect Immun. 1999 Dec;67(12):6257-63.

IHO et al., Oligodeoxynucleotides containing palindromic sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro. J Immunol. 1999 Oct 1;163(7):3642-52.

IMAI et al., Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998 Jul 15;129(2):94-9.

ITO et al., CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans. Infect Immun. 2005 Sep;73(9):6154-6.

IVERSEN et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res Dev. 1994 Spring;4(1):43-52.

JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998 Sep 15;161(6):3042-9.

JAKOB et al., Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int

EXAMINER:

/E.L./

DATE CONSIDERED:

06/09/2010

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	15	of	23				

	Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):457-61.	
	JIANG et al., Enhancing immunogenicity by CpG DNA. Curr Opin Mol Ther. 2003 Apr;5(2):180-5.	
	JIAO et al., Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol. 2004 Jun;85(Pt 6):1545-53.	
	JOHNSON et al., Non-specific resistance against microbial infections induced by polyribonucleotide complexes. In: Immunopharmacology of infection diseases: Vaccine adjuvants and modulators of non-specific resistance. 1987: 291-301.	
	JOSEPH et al., Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine. 2002 Sep 10;20(27-28):3342-54.	
	KANDIMALLA et al., Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr Opin Mol Ther. 2002 Apr;4(2):122-9.	
	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82.	
	KIMURA et al., Binding of oligoguanilate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. J Biochem (Tokyo). 1994 Nov;116(5):991-4.	
	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 2000 Jun;13(5):289-96.	
	KLINMAN et al., Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004 Apr;4(4):249-58.	
	KLINMAN et al., Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun. 1999 Nov;67(11):5658-63.	
	KLINMAN et al., Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Springer Semin Immunopathol. 2000;22(1-2):173-83.	
	KLINMAN et al., Immune recognition of foreign DNA: a cure for bioterrorism? Immunity. 1999 Aug;11(2):123-9.	
	KLINMAN et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol. 1997 Apr 15;158(8):3635-9.	
	KLINMAN et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83.	
	KNIFE et al., eds., Fields' Virology. 2001;1:1564.	
	KOVARIK et al., CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol. 1999 Feb 1;162(3):1611-7.	
	KRANZER et al., CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology. 2000 Feb;99(2):170-8.	
	KRIEG et al., Immune effects and therapeutic applications of CpG motifs in bacterial DNA. Immunopharmacology. 2000 Jul 25;48(3):303-5.	

EXAMINER: /E.L/	DATE CONSIDERED: 06/09/2010
------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	16	of	23				

		KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel unmethylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
		KRIEG et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 1996 Summer;6(2):133-9.	
		KRIEG et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev. 1995 Winter;5(4):241.	
		KRIEG et al., Leukocyte stimulation by oligodeoxynucleotides. In: Applied Antisense Oligonucleotide Technology. 1998:431-48.	
		KRIEG et al., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546-9.	
		KRIEG et al., The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998 Jan;6(1):23-7.	
		KRIEG, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med. 1996 Aug;128(2):128-33.	
		KRIEG et al., Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb;1(1):56-63.	
		KRIEG et al., CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-60.	
		KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct;21(10):521-6.	
		KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. In: Antisense Research and Application. Crooke, Ed. 1998:243-62.	
		KRIEG et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol. 1989 Oct 15;143(8):2448-51.	
		KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996:116.	
		KRIEG et al., Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 Feb;3(1):15-24.	
		KRIEG, Chapter 7: CpG oligonucleotides as immune adjuvants. Ernst Schering Research Found Workshop 2001; 30:105-18.	
		KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2001 Nov 8;19(6):618-22.	
		KRIEG et al., Chapter 17: Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
		KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	
		KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
		KRIEG, The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb;12(1):35-43.	

EXAMINER:	/E.L./	DATE CONSIDERED:	06/09/2010
-----------	--------	------------------	------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
APPLICANT: Ahluwalia et al.			
GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	17	of	23

	KRIEG et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. 1999 Nov;84(2):113-20.	
	KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.	
	KRIEG et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 1;161(5):2428-34.	
	KRIEG et al., CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb;7(2):64-5.	
	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.	
	KRIEG et al., How to exclude immunostimulatory and other nonantisense effects of antisense oligonucleotides. Manual of Antisense. 1999:79-89.	
	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
	KRIEG et al., Infection. In: McGraw Hill Book. 1996:242-3.	
	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
	KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
	KRIEG, Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.	
	KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71.	
	KRIEG et al., Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. Antisense Nucleic Acid Drug Dev. 1997 Apr;7(2):115-23.	
	KRIEG, Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52.	
	KRIEG, Antimicrobial applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007 Jul;4(3):289-94.	
	KRUG et al., Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63.	
	KRUG et al., Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct;31(10):3026-37.	
	KUHOBER et al., DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J Immunol. 1996 May 15;156(10):3687-95. Abstract only.	
	KULKARNI et al., Effect of dietary nucleotides on response to bacterial infections. JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):169-71.	
	KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res. 1992 Nov;83(11):1128-31.	
	KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40.	

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
-------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	18	of	23				

		KWANT et al., Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine. 2004 Aug 13;22(23-24):3098-104.	
		LAMM et al., Mechanisms of Ig-A mediated mucosal defense. Vaccine Research. 1992;1(3):169-173.	
		LE BORGNE et al., In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen. Virology. 1998 Jan 20;240(2):304-15. Abstract only.	
		LEE et al., Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations. Immunology. 1998 Jul;94(3):285-9.	
		LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep;27(9):2340-4.	
		LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol. 1997 Dec;27(12):3420-6.	
		LIPFORD et al., Bacterial DNA as immune cell activator. Trends Microbiol. 1998 Dec;6(12):496-500.	
		LIU et al., Immunization of non-human primates with DNA vaccines. Vaccine. 1997 Jun;15(8):909-12.	
		MA et al., DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine. 2002 Sep 10;20(27-28):3263-71.	
		MAJOR et al. Chapter 34 Hepatitis C Viruses. in Fields' Virology. 2001; 1:1127-61	
		MALANCHERE-BRES et al., CpG oligodeoxynucleotides with hepatitis B surface antigen (HbsAg) for vaccination in HbsAg-transgenic mice. J Virol. 2001 Jul;75(14):6482-91.	
		MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol. 1999 Jul;11(7):1111-8.	
		MATSUKURA et al., Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4244-8.	
		McCLUSKIE et al., CpG DNA as mucosal adjuvant. Immunol Letts. 1999;69(1):30-1. Abstract #5.2	
		McCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998 Nov 1;161(9):4463-6.	
		McCLUSKIE et al., CpG DNA as mucosal adjuvant. Vaccine. 2000;18: 231-7.	
		McCLUSKIE et al., Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 2000 Oct 15;19(4-5):413-22.	
		McCLUSKIE et al., Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol. 1998;11(4):245-52.	
		McCLUSKIE et al., CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000 Nov 22;19(7-8):950-7.	
		McCLUSKIE et al., The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.	

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
------------------	-----------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	19	of	23				

		Vaccine. 2001 Mar 21;19(17-19):2657-60.	
		McCLUSKIE et al., The use of CpG DNA as a mucosal vaccine adjuvant. Curr Opin Investig Drugs. 2001 Jan;2(1):35-9.	
		McCLUSKIE et al., Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85.	
		McCLUSKIE et al., The role of CpG in DNA vaccines. Springer Semin Immunopathol. 2000;22(1-2):125-32.	
		McCLUSKIE et al., Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848). Antiviral Res. 2006 Feb;69(2):77-85. Epub 2005 Dec 5.	
		McHUTCHISON et al., Final results of a multi-center phase 1B, randomized, placebo-controlled, dose-escalation trial of CpG 10101 in patients with chronic hepatitis C virus. 41 st Annual Meeting of European Association for the Study of the Liver (EASL). 2006 April 30, Vienna, Austria; Presented Abstract #111.	
		McHUTCHISON et al., Early clinical results with CpG 10101, a new investigational antiviral TLR9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus. 12 th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD). 2006 July 3, Paris, France; Presented Abstract #O105.	
		MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol. 1993 Mar;147(1):148-57.	
		MOJCIK et al., Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. Clin Immunol Immunopathol. 1993 May;67(2):130-6.	
		MOLDOVEANU et al., CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 1998 Jul;16(11-12):1216-24.	
		MOSEMAN et al., Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 2004 Oct 1;173(7):4433-42.	
		MOSS et al., In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. Vaccine. 2000 Jan 6;18(11-12):1081-7.	
		NESBURN et al., Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine. 2005 Jan 4;23(7):873-83.	
		OXENIUS et al., CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol. 1999 May;73(5):4120-6.	
		PAYETTE et al., History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord. 2001 Nov;1(3):241-7.	
		PISETSKY et al., The immunologic properties of DNA. J Immunol. 1996 Jan 15;156(2):421-3.	
		PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63.	
		PISETSKY et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 1994;54(2):101-7.	

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
---------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	20	of	23				

		PISETSKY, Immunologic consequences of nucleic acid therapy. Antisense Res Dev. 1995 Fall;5(3):219-25.	
		PISETSKY et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. Mol Biol Rep. 1993 Oct;18(3):217-21.	
		PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. Immunol Res. 1999;19(1):35-46.	
		PISETSKY et al., The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology. 1998 Nov;40(3):199-208.	
		POLANCZYK et al., Immunostimulatory effects of DNA and CpG motifs. Cent Eur J of Immunol. 2000;25(3):160-6.	
		RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40.	
		RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract 615.	
		REES et al., CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res. 2005 Feb;65(2):87-95.	
		ROFFI et al., Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology. 1995 Mar;21(3):645-9.	
		ROMAN et al., Immunostimulatory DNA sequences function as T helper-I-promoting adjuvants. Nat Med. 1997 Aug;3(8):849-54.	
		ROTHENFUSSEER et al., Recent advances in immunostimulatory CpG oligonucleotides. Curr Opin Mol Ther. 2003 Apr;5(2):98-106.	
		RYNKIEWICZ et al., Marked enhancement of antibody response to anthrax vaccine adsorbed with CPG 7909 in healthy volunteers. 45 th Intersci. Conf. Antimicrob. Agents Chemother. 2005 Sep. 21-24; New Orleans, Louisiana. Meeting Poster.	
		SAJIC et al., Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol. 2003 Dec;71(4):561-8.	
		SATO et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 1996 Jul 19;273(5273):352-4.	
		SATOH et al., The study of mechanisms in CpG oligodeoxynucleotides-induced aggravation in murine allergic contact dermatitis to 2,4-dinitrofluorobenzene. Fukushima Igaku Zasshi. 2002;52(3):237-50.	Y-Abstract
		SCHEULE, The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev. 2000 Nov 15;44(2-3):119-34.	
		SCHIRMBECK et al., Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol. 1995 Oct;69(10):5929-34.	
		SCHLAACK et al., Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells. J Med Virol. 1998 Oct;56(2):112-7.	
		SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can	

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
------------------	-----------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	21	of	23				

		minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. <i>J Immunol.</i> 1999 Jul 1;163(1):224-31.	
		SCHWARTZ et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. <i>J Clin Invest.</i> 1997 Jul 1;100(1):68-73.	
		SESTER et al., Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. <i>J Immunol.</i> 2000 Oct 15;165(8):4165-73.	
		SIEGRIST et al., Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. <i>Vaccine.</i> 2004 Dec 16;23(5):615-22.	
		SINGH et al., Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. <i>Pharm Res.</i> 2001 Oct;18(10):1476-9.	
		SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. <i>J Interferon Cytokine Res.</i> 1996 Oct;16(10):799-803.	
		SPARWASSER et al., Bacterial DNA causes septic shock. <i>Nature.</i> 1997 Mar 27;386(6623):336-7.	
		SPARWASSER et al., Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. <i>Eur J Immunol.</i> 1998 Jun;28(6):2045-54.	
		SPARWASSER et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol.</i> 1997 Jul;27(7):1671-9.	
		STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. <i>Antisense Res Dev.</i> 1994 Summer;4(2):67-9.	
		STEIN et al., Non-antisense effects of oligodeoxynucleotides. <i>Antisense Technology.</i> 1997; Ch.11: 241-64.	
		STEIN et al., Antisense oligonucleotides as therapeutic agents—is the bullet really magical? <i>Science.</i> 1993 Aug 20;261(5124):1004-12.	
		STEVCEVA et al., Mucosal HIV vaccines: where are we now? <i>Curr HIV Res.</i> 2004 Jan;2(1):1-10.	
		SUN et al., Type I interferon-mediated stimulation of T cells by CpG DNA. <i>J Exp Med.</i> 1998 Dec 21;188(12):2335-42.	
		SUN et al., Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. <i>Springer Semin Immunopathol.</i> 2000;22(1-2):77-84.	
		TACKET et al., Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. <i>Vaccine.</i> 1999 Jul 16;17(22):2826-9.	
		TOKUNAGA et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells. <i>Microbiol Immunol.</i> 1992;36(1):55-66.	
		TOKUNAGA, Response of the organism to DNA – With a focus on immunostimulatory DNA. <i>Kansen Ensho Meneki.</i> 2001 Autumn; 31(3): 1-12. Japanese.	Y
		UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. <i>Curr Opin Drug Discov Devel.</i> 2003 Mar;6(2):204-17.	
		VERTHEL YI et al., CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. <i>AIDS.</i> 2004 Apr 30;18(7):1003-8.	
		VERTHEL YI et al., Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. <i>J Immunol.</i> 2001 Feb 15;166(4):2372-7.	

EXAMINER: /E.L./	DATE CONSIDERED: 06/09/2010
-------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	22	of	23				

		VOLLMER et al., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. <i>Antisense Nucleic Acid Drug Dev.</i> 2002 Jun;12(3):165-75.	
		VOLLMER et al., Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. <i>Antimicrob Agents Chemother.</i> 2004 Jun;48(6):2314-7.	
		VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. <i>Eur J Immunol.</i> 2004 Jan;34(1):251-62.	
		VOLLMER et al., Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). <i>Oligonucleotides.</i> 2004 Spring;14(1):23-31.	
		VOLLMER et al., Identification of a new class of CpG oligonucleotides capable of inducing both B cell proliferation and high IFN-alpha secretion from PBMC of HCV chronic carriers. <i>Antivir Ther</i> 2002; 7:L115	
		VOLLMER, TLR9 in health and disease. <i>Int Rev Immunol.</i> 2006 May-Aug;25(3-4):155-81.	
		WAGNER, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. <i>Curr Opin Microbiol.</i> 2002 Feb;5(1):62-9.	
		WANG et al., CpG oligonucleotides partially inhibit growth of <i>Mycobacterium tuberculosis</i> , but not <i>Salmonella</i> or <i>Listeria</i> , in human monocyte-derived macrophages. <i>FEMS Immunol Med Microbiol.</i> 2005 Aug 1;45(2):303-10.	
		WARREN et al., APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. <i>J Immunol.</i> 2000 Dec 1;165(11):6244-51.	
		WEERATNA et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1998 Aug;8(4):351-6.	
		WEERATNA et al., CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. <i>Immunol Cell Biol.</i> 2003 Feb;81(1):59-62.	
		WEERATNA et al., CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. <i>FEMS Immunol Med Microbiol.</i> 2001 Dec;32(1):65-71.	
		WEERATNA et al., CpG DNA induces stronger immune responses with less toxicity than other adjuvants. <i>Vaccine.</i> 2000 Mar 6;18(17):1755-62.	
		WEERATNA et al., Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. <i>FEMS Immunol Med Microbiol.</i> 2001 Apr;30(3):241-7	
		WEIGHARDT et al., Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. <i>J Immunol.</i> 2000 Oct 15;165(8):4537-43.	
		WEINER et al., The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. <i>J Leukoc Biol.</i> 2000 Oct;68(4):455-63.	
		YAMAMOTO et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. <i>Microbiol Immunol.</i> 1994;38(10):831-6.	
		YAMAMOTO et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. <i>J Immunol.</i> 1992 Jun 15;148(12):4072-6.	
		YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of	Y

EXAMINER:	DATE CONSIDERED:
/E.L./	06/09/2010

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/532,746		ATTY. DOCKET NO.: C1037.70035US01	
				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683	
				APPLICANT: Ahluwalia et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	23	of	23				

		action of oligonucleotide fraction extracted from <i>Mycobacterium bovis</i> BCG] Kekkaku. 1994 Sep;69(9):571-4. Japanese.	
		YAMAMOTO et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. <i>Antisense Res Dev.</i> 1994 Summer;4(2):119-22.	
		YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. <i>Jpn J Cancer Res.</i> 1994 Aug;85(8):775-9.	
		YI et al., Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. <i>J Immunol.</i> 1998 Nov 1;161(9):4493-7.	
		YI et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. <i>J Immunol.</i> 1996 Dec 15;157(12):5394-402.	
		YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. <i>J Immunol.</i> 1996 Jan 15;156(2):558-64.	
		YI et al., CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. <i>J Immunol.</i> 1998 Jun 15;160(12):5898-906.	
		YI et al., CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. <i>J Immunol.</i> 1996 Dec 1;157(11):4918-25.	
		YU et al., Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. <i>Bioorg Med Chem Lett.</i> 2000 Dec 4;10(23):2585-8.	
		ZELPHATTI et al., Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. <i>Antisense Res Dev.</i> 1993 Winter;3(4):323-38. Abstract only.	
		ZHANG et al., Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. <i>Antimicrob Agents Chemother.</i> 1999 Feb;43(2):347-53.	
		ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):495-502.	
		ZHU et al., Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. <i>Int Immunopharmacol.</i> 2004 Jul;4(7):851-62.	
		ZIMMERMANN et al., CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. <i>J Immunol.</i> 1998 Apr 15;160(8):3627-30.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /Emily Le/	DATE CONSIDERED: 06/09/2010
-----------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.